TY - JOUR
AU - R. R. Cook
AU - C. Foot
AU - O. A. Arah
AU - K. Humphreys
AU - K. E. Rudolph
AU - S. X. Luo
AU - J. I. Tsui
AU - X. A. Levander
AU - P. T. Korthuis
A1 - 
AD - Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Sam Jackson Hall, Suite 3370, 3245 SW Pavilion Loop, Portland, OR, 97239, USA. cookry@ohsu.edu.;Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Sam Jackson Hall, Suite 3370, 3245 SW Pavilion Loop, Portland, OR, 97239, USA.;Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.;Division of Physical Sciences, Department of Statistics, UCLA College, Los Angeles, CA, USA.;Research Unit for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.;Center for Innovation to Implementation, VA Palo Alto Health Care System, Palo Alto, CA, USA.;Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.;Department of Epidemiology, School of Public Health, Columbia University, New York, NY, USA.;Division on Substance Use Disorders, Department of Psychiatry, Columbia University, New York, USA.;Department of Medicine, University of Washington, Seattle, WA, USA.
AN - 36788634
BT - Addict Sci Clin Pract
C5 - Opioids & Substance Use;Healthcare Disparities
CP - 1
DA - Feb 14
DO - 10.1186/s13722-023-00364-3
DP - NLM
ET - 20230214
IS - 1
JF - Addict Sci Clin Pract
LA - eng
PY - 2023
SN - 1940-0632 (Print);1940-0632
SP - 11
ST - Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
T1 - Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
T2 - Addict Sci Clin Pract
TI - Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
U1 - Opioids & Substance Use;Healthcare Disparities
U3 - 10.1186/s13722-023-00364-3
VL - 18
VO - 1940-0632 (Print);1940-0632
Y1 - 2023
ER -